Navigation Links
Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
Date:2/26/2010

According to the New York Times, hundreds of people taking the type-2 diabetes drug Avandia® suffer heart attacks and heart failure as result of its use. For more information, contact the Maher Law firm.

(PRWEB) February 26, 2010 -- Maher Law Firm attorneys are investigating possible Avandia® claims. Contact an experienced personal injury lawyer – one familiar with Avandia®’s potentially fatal side effects – if you or a loved one has experienced heart problems after Avandia® use.

The article, published in the Friday edition (02/19/2010), cites confidential government reports stating that if Avandia® users were instead treated with Actos, a similar pill, about 500 heart attacks and 300 cases of heart failure would be averted each month.

An internal Food and Drug Administration (FDA) report recommends Avandia®, or “rosiglitazone” be removed from the market. The authors, Dr. David Graham and Dr. Kate Gelperin, both urge Avandia®’s withdrawal.

According to the New York Times, the reports have ignited debate within the FDA as to what to do about Avandia®. While some officials support its withdrawal, others believe more testing is needed.

What is Avandia®?
Avandia®, or rosiglitazone, is a popular prescription drug, manufactured by the U.K. pharmaceutical company, GlaxoSmithKline, used to treat “type-2” or “adult-onset” diabetes.

Avandia® was once one of the biggest-selling drugs in the world. Driven in part by a multimillion-dollar advertising campaign, sales were $3.2 billion in 2006. However, after a 2007 study by a Cleveland Clinic cardiologist linked the drug to heart problems prompting an FDA warning, sales plummeted. A committee of independent experts found in 2007 that Avandia might increase the risk of heart attack but recommended that it remain on the market, and an FDA oversight board voted 8 to 7 to accept that advice.

FDA Urges Patients Not to Discontinue Avandia® Use
The FDA said Monday that for now, patients should not stop taking Avandia® without first speaking with their healthcare professional. Patients should discuss any questions or concerns with their physician. Report any side effects to FDA’s MedWatch program.

Senate: Maker Should Have Warned Patients
Senate investigators concluded that GlaxoSmithKline should have warned patients earlier of Avandia®’s potential side effects. The bipartisan multiyear Senate investigation states GlaxoSmithKline failed to warn patients years earlier that Avandia was potentially deadly.

“Instead, G.S.K. executives attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a competing drug might reduce cardiovascular risk,” concludes the report, which was overseen by Senator Max Baucus, a Montana Democrat, and Senator Charles E. Grassley, an Iowa Republican.

Avandia lawyer

Contact an experienced personal injury lawyer – one familiar with Avandia®’s potentially fatal side effects – if you or a loved one has experienced heart problems after Avandia® use.

###

Read the full story at http://www.prweb.com/releases/PossibleAvandiaRecall/02/prweb3642334.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. YazTalk Warns Women of Life Threatening Side Effects
2. FDA CONSUMER HEALTH INFORMATION: FDA Warns Consumers About Unsafe Counterfeit Alli
3. Security Choice Warns Against Dangers of Carbon Monoxide
4. FDA Warns Public of Continued Extortion Scam by FDA Impersonators
5. Patients Medical Warns Against The Manhattan Diet
6. Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly
7. Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America
8. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
9. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis
10. Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN
11. Throw a Yellow Flag on Football-related Head Injuries, Warns the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... the organization behind the New England Journal of Medicine and NEJM Journal Watch, ... Knowledge+ Pediatrics Board Review was created by a panel of pediatricians from leading ...
(Date:3/27/2017)... ... 27, 2017 , ... Osteitis pubis may be commonplace and ... it occurs when the muscles around the pelvis become inflamed. Over time, untreated ... torso, as well as accompanying tenderness and weakness. Without proper intervention, it can ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
(Date:3/27/2017)... ... 27, 2017 , ... Golden Triangle Emergency Center will be ... 3rd to commemorate the two-year anniversary of the facility. The event will feature ... great years while also familiarizing themselves with the facility. , In the two ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
(Date:3/27/2017)... , March 27, 2017   Genprex, Inc. , a ... Julien Pham , MD, the Company,s Chief Operating Officer, is ... conferences. Sachs 5th Annual Cancer BioPartnering & Investment ... New York, NY ... BioCentury 24th Annual Future Leaders in Biotech ...
Breaking Medicine Technology: